



Dr. Karl-Rudolf (Rudi) Erlemann is Vice President of Business Development and External Scientific Affairs at InSymbiosis, a collaborative drug development company which employs a functional outsourcing model to develop novel medications for international biotech and pharma companies. In addition he is partner at InSynchrony Ventures. In his current role, Rudi develops new relationships with partner companies, performs scientific due diligence on investment opportunities and builds relationships with external consultants. Before this role, he managed drug development programs ranging from early target validation, ADME, pharmacology, CMC, bioanalysis through to all aspects of safety testing. Prior to joining the

InSymbiosis team, he was with the Drug Metabolism and Pharmacokinetics group at Charles River Laboratories where he managed in vitro DMPK studies and developed biochemical assays.

After obtaining a M.Sc. in biophysics he received his Ph.D. in biochemistry from the Humboldt-University in Berlin, Germany with the experimental work carried out at the McGill University in Montreal. His academic research focused on the regulation of the formation of inflammatory mediators by oxidative stress using a pharmacological approach.